Oncolys BioPharma Inc. (4588.T)
JPY 602.0
(-1.79%)
JPY 602.0
(-1.79%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 315.17 Million JPY | -19.94% |
| 2022 | 393.65 Million JPY | -21.81% |
| 2021 | 503.47 Million JPY | -4.11% |
| 2020 | 525.07 Million JPY | -0.6% |
| 2019 | 528.22 Million JPY | 31.54% |
| 2018 | 401.58 Million JPY | -11.69% |
| 2017 | 454.73 Million JPY | 17.07% |
| 2016 | 388.44 Million JPY | -9.4% |
| 2015 | 428.75 Million JPY | -21.87% |
| 2014 | 548.79 Million JPY | 5.89% |
| 2013 | 518.24 Million JPY | 77.56% |
| 2012 | 291.87 Million JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 365.8 Million JPY | 26.88% |
| 2024 Q1 | 288.29 Million JPY | -8.53% |
| 2023 Q2 | 439.1 Million JPY | 22.16% |
| 2023 Q1 | 359.44 Million JPY | -8.69% |
| 2023 Q4 | 315.17 Million JPY | -1.98% |
| 2023 Q3 | 321.53 Million JPY | -26.77% |
| 2023 FY | 315.17 Million JPY | -19.94% |
| 2022 Q4 | 393.65 Million JPY | -4.27% |
| 2022 FY | 393.65 Million JPY | -21.81% |
| 2022 Q1 | 458.37 Million JPY | -8.96% |
| 2022 Q2 | 537.08 Million JPY | 17.17% |
| 2022 Q3 | 411.21 Million JPY | -23.44% |
| 2021 Q2 | 560.34 Million JPY | -5.2% |
| 2021 Q3 | 526.35 Million JPY | -6.07% |
| 2021 Q4 | 503.47 Million JPY | -4.35% |
| 2021 FY | 503.47 Million JPY | -4.11% |
| 2021 Q1 | 591.09 Million JPY | 12.57% |
| 2020 Q1 | 593.93 Million JPY | 12.44% |
| 2020 FY | 525.07 Million JPY | -0.6% |
| 2020 Q2 | 568.16 Million JPY | -4.34% |
| 2020 Q3 | 542.45 Million JPY | -4.53% |
| 2020 Q4 | 525.07 Million JPY | -3.2% |
| 2019 Q1 | 591.3 Million JPY | 47.24% |
| 2019 Q4 | 528.22 Million JPY | -1.34% |
| 2019 Q3 | 535.38 Million JPY | -6.07% |
| 2019 FY | 528.22 Million JPY | 31.54% |
| 2019 Q2 | 569.94 Million JPY | -3.61% |
| 2018 Q3 | 411.86 Million JPY | -2.56% |
| 2018 Q4 | 401.58 Million JPY | -2.5% |
| 2018 FY | 401.58 Million JPY | -11.69% |
| 2018 Q2 | 422.66 Million JPY | -4.74% |
| 2018 Q1 | 443.71 Million JPY | -2.42% |
| 2017 Q2 | 473.94 Million JPY | 23.12% |
| 2017 FY | 454.73 Million JPY | 17.07% |
| 2017 Q4 | 454.73 Million JPY | -2.36% |
| 2017 Q3 | 465.74 Million JPY | -1.73% |
| 2017 Q1 | 384.93 Million JPY | -0.9% |
| 2016 Q4 | 388.44 Million JPY | -2.06% |
| 2016 Q3 | 396.62 Million JPY | -2.69% |
| 2016 Q2 | 407.57 Million JPY | -1.8% |
| 2016 Q1 | 415.04 Million JPY | -3.2% |
| 2016 FY | 388.44 Million JPY | -9.4% |
| 2015 Q4 | 428.75 Million JPY | -1.87% |
| 2015 Q2 | 447.85 Million JPY | -1.63% |
| 2015 FY | 428.75 Million JPY | -21.87% |
| 2015 Q3 | 436.92 Million JPY | -2.44% |
| 2015 Q1 | 455.28 Million JPY | -17.04% |
| 2014 FY | 548.79 Million JPY | 5.89% |
| 2014 Q2 | 462.82 Million JPY | -2.05% |
| 2014 Q1 | 472.49 Million JPY | -8.83% |
| 2014 Q4 | 548.79 Million JPY | -0.5% |
| 2014 Q3 | 551.57 Million JPY | 19.18% |
| 2013 FY | 518.24 Million JPY | 77.56% |
| 2013 Q4 | 518.24 Million JPY | 0.0% |
| 2012 FY | 291.87 Million JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 2.46 Billion JPY | 87.239% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 3.69 Billion JPY | 91.481% |
| Linical Co., Ltd. | 3 Billion JPY | 89.501% |
| Trans Genic Inc. | 2.25 Billion JPY | 86.036% |
| MEDINET Co., Ltd. | 2.3 Million JPY | -13561.465% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.47 Billion JPY | 87.249% |
| AnGes, Inc. | 362.67 Million JPY | 13.099% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | -194.968% |
| Nxera Pharma Co., Ltd. | 73.97 Billion JPY | 99.574% |
| Immuno-Biological Laboratories Co., Ltd. | 235.98 Million JPY | -33.557% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 71.579% |
| Carna Biosciences, Inc. | 182.97 Million JPY | -72.251% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 885.12 Million JPY | 64.392% |
| RaQualia Pharma Inc. | 367.71 Million JPY | 14.29% |
| Chiome Bioscience Inc. | 291 Million JPY | -8.306% |
| Kidswell Bio Corporation | 2.57 Billion JPY | 87.76% |
| PeptiDream Inc. | 22.79 Billion JPY | 98.618% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 665 Million JPY | 52.606% |
| Healios K.K. | 4.53 Billion JPY | 93.046% |
| BrightPath Biotherapeutics Co., Ltd. | 112.5 Million JPY | -180.151% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 142.85 Million JPY | -120.625% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 97.54 Million JPY | -223.112% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 933.3 Million JPY | 66.231% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 968 Million JPY | 67.441% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 723.93 Million JPY | 56.464% |
| StemCell Institute Inc. | 8.78 Million JPY | -3488.001% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 151.25 Million JPY | -108.377% |